Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab plus dacarbazine in progressive metastatic pancreatic neuroendocrine tumors
2017-001207-68Phase 2Active
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab and dacarbazine in islet cell tumor, sponsored by Martin Luther University Halle-Wittenberg. Primary endpoint: Disease control rate. Started Jan 2018; status: active.
02
Drugs
ramucirumabdacarbazine
03
Conditions
islet cell tumor
Beyond the preview
Go deeper on 2017-001207-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001207-68.